107 related articles for article (PubMed ID: 2066805)
21. Thiolations, 99mTc labelings, and animal in vivo biodistributions of divalent monoclonal antibody fragments.
Govindan SV; Goldenberg DM; Grebenau RC; Hansen HJ; Griffiths GL
Bioconjug Chem; 1996; 7(3):290-7. PubMed ID: 8816950
[TBL] [Abstract][Full Text] [Related]
22. Site-specific modifications of light chain glycosylated antilymphoma (LL2) and anti-carcinoembryonic antigen (hImmu-14-N) antibody divalent f1agments.
Govindan SV; Goldenberg DM; Griffiths GL; Leung SO; Losman MJ; Hansen HJ
Cancer Res; 1995 Dec; 55(23 Suppl):5721s-5725s. PubMed ID: 7493334
[TBL] [Abstract][Full Text] [Related]
23. Labeling and stability of radiolabeled antibody fragments by a direct 99mTc-labeling method.
Pak KY; Nedelman MA; Tam SH; Wilson E; Daddona PE
Int J Rad Appl Instrum B; 1992 Aug; 19(6):669-77. PubMed ID: 1522021
[TBL] [Abstract][Full Text] [Related]
24. Development of radiochemically pure antibodies.
Eckelman WC
Cancer Res; 1990 Feb; 50(3 Suppl):780s-782s. PubMed ID: 2297723
[TBL] [Abstract][Full Text] [Related]
25. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
26. Chemical modification to reduce renal uptake of disulfide-bonded variable region fragment of anti-Tac monoclonal antibody labeled with 99mTc.
Kim IS; Yoo TM; Kobayashi H; Kim MK; Le N; Wang QC; Pastan I; Carrasquillo JA; Paik CH
Bioconjug Chem; 1999; 10(3):447-53. PubMed ID: 10346877
[TBL] [Abstract][Full Text] [Related]
27. Animal evaluation of technetium-99m triamide mercaptide complexes as potential renal imaging agents.
Eshima D; Taylor A; Fritzberg AR; Kasina S; Hansen L; Sorenson JF
J Nucl Med; 1987 Jul; 28(7):1180-6. PubMed ID: 2955085
[TBL] [Abstract][Full Text] [Related]
28. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives.
Behr TM; Sharkey RM; Juweid ME; Blumenthal RD; Dunn RM; Griffiths GL; Bair HJ; Wolf FG; Becker WS; Goldenberg DM
Cancer Res; 1995 Sep; 55(17):3825-34. PubMed ID: 7641200
[TBL] [Abstract][Full Text] [Related]
29. 99mTc-labeling and in vitro and in vivo evaluation of HYNIC- and (Nalpha-His)acetic acid-modified [D-Glu1]-minigastrin.
von Guggenberg E; Behe M; Behr TM; Saurer M; Seppi T; Decristoforo C
Bioconjug Chem; 2004; 15(4):864-71. PubMed ID: 15264875
[TBL] [Abstract][Full Text] [Related]
30. An N2S2 bifunctional chelator for technetium-99m and rhenium: complexation, conjugation, and epimerization to a single isomer.
Luyt LG; Jenkins HA; Hunter DH
Bioconjug Chem; 1999; 10(3):470-9. PubMed ID: 10346880
[TBL] [Abstract][Full Text] [Related]
31. Direct labeling of monoclonal antibodies with technetium-99m by photoactivation.
Sykes TR; Woo TK; Baum RP; Qi P; Noujaim AA
J Nucl Med; 1995 Oct; 36(10):1913-22. PubMed ID: 7562064
[TBL] [Abstract][Full Text] [Related]
32. Somatostatin receptor-binding peptides suitable for tumor radiotherapy with Re-188 or Re-186. Chemistry and initial biological studies.
Cyr JE; Pearson DA; Wilson DM; Nelson CA; Guaraldi M; Azure MT; Lister-James J; Dinkelborg LM; Dean RT
J Med Chem; 2007 Mar; 50(6):1354-64. PubMed ID: 17315859
[TBL] [Abstract][Full Text] [Related]
33. Further studies on the protein conjugation of hydroxamic acid bifunctional chelating agents: group-specific conjugation at two different loci.
Safavy A; Khazaeli MB; Kirk M; Coward L; Buchsbaum DJ
Bioconjug Chem; 1999; 10(1):18-23. PubMed ID: 9893959
[TBL] [Abstract][Full Text] [Related]
34. Technetium-99m labeling of DNA oligonucleotides.
Hnatowich DJ; Winnard P; Virzi F; Fogarasi M; Sano T; Smith CL; Cantor CR; Rusckowski M
J Nucl Med; 1995 Dec; 36(12):2306-14. PubMed ID: 8523124
[TBL] [Abstract][Full Text] [Related]
35. Improved tumor targeting with chemically cross-linked recombinant antibody fragments.
King DJ; Turner A; Farnsworth AP; Adair JR; Owens RJ; Pedley RB; Baldock D; Proudfoot KA; Lawson AD; Beeley NR
Cancer Res; 1994 Dec; 54(23):6176-85. PubMed ID: 7954464
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of NR-LU-10 with the Neoprobe gamma detector in a mouse model.
Lange MK; Sandhu A; Sampsel J; Hinkle G; Ignaszewski J; Martin E; Sandhu P; Martin EW
J Surg Res; 1993 Aug; 55(2):205-13. PubMed ID: 8412101
[TBL] [Abstract][Full Text] [Related]
37. An improved synthesis of NHS-MAG3 for conjugation and radiolabeling of biomolecules with (99m)Tc at room temperature.
Wang Y; Liu X; Hnatowich DJ
Nat Protoc; 2007; 2(4):972-8. PubMed ID: 17446896
[TBL] [Abstract][Full Text] [Related]
38. Pyrazolyl derivatives as bifunctional chelators for labeling tumor-seeking peptides with the fac-[M(CO)3]+ moiety (M = 99mTc, Re): synthesis, characterization, and biological behavior.
Alves S; Paulo A; Correia JD; Gano L; Smith CJ; Hoffman TJ; Santos I
Bioconjug Chem; 2005; 16(2):438-49. PubMed ID: 15769099
[TBL] [Abstract][Full Text] [Related]
39. Monoclonal antibodies labeled with rhenium-186 using the MAG3 chelate: relationship between the number of chelated groups and biodistribution characteristics.
van Gog FB; Visser GW; Klok R; van der Schors R; Snow GB; van Dongen GA
J Nucl Med; 1996 Feb; 37(2):352-62. PubMed ID: 8667076
[TBL] [Abstract][Full Text] [Related]
40. A peptide-based bifunctional chelating agent for 99mTc- and 186Re-labeling of monoclonal antibodies.
Ram S; Buchsbaum DJ
Cancer; 1994 Feb; 73(3 Suppl):769-73. PubMed ID: 8306258
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
